Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215767 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice
A Phase 3 study of Dentin Hypersensitivity, sponsored by HALEON.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
- 3
- Study locations
NCT07215767: Recruiting Phase 3 study of Dentin Hypersensitivity, sponsored by HALEON.
NCT07215767 is a Phase 3 study of Dentin Hypersensitivity that is actively recruiting participants, run by HALEON. The registered enrollment target is 850 participants, above the 175-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (386% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215767, a Phase 3 study of Dentin Hypersensitivity, is actively recruiting participants, sponsored by HALEON.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this clinical study is to demonstrate the superior antihypersensitivity efficacy of a novel stannous fluoride (SnF2) and potassium nitrate (KNO3) dentifrice (Investigational Product), compared to SnF2 only, KNO3 only and Vehicle dentifrices, after 8 weeks twice daily use.
Primary Outcome
Evaporative (air) sensitivity will be assessed by the participant's response to an evaporative (air) stimulus administered by the clinical examiner. Participant response will be evaluated immediately following application of the stimulus using the Schiff sensitivity scale (0=Participant does not respond to air stimulation, 1=Participant responds to air stimulus but does not request discontinuation of stimulus, 2=Participant responds to air stimulus and requests discontinuation or moves from stim
Conditions Studied
Interventions
- DRUG Stannous fluoride and Potassium nitrate Dentifrice
- DRUG Stannous fluoride Dentifrice
- DRUG Potassium nitrate Dentifrice
- DRUG Vehicle Dentifrice
Study Locations (3)
Florida
- All Sum Research Limited - Melbourne
Indiana
- Salus Research, Inc. - Fort Wayne
Nevada
- Silverstone Research - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What NCT07215767 shows while recruiting
NCT07215767 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 175-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (386% higher).
The record links to 1 condition, with Dentin Hypersensitivity appearing as the primary indexed condition, and to 4 interventions - of which Stannous fluoride and Potassium nitrate Dentifrice is the first listed.
NCT07215767 reports a single indexed study location in Florida, Indiana, Nevada.
Frequently Asked Questions
What is clinical trial NCT07215767 about?
NCT07215767 is a clinical study titled "Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice". The aim of this clinical study is to demonstrate the superior antihypersensitivity efficacy of a novel stannous fluoride (SnF2) and potassium nitrate (KNO3) dentifrice (Investigational Product), compared to SnF2 only, KNO3 only and Vehicle dentifrices, after 8 weeks twice daily use.
What is the current status of trial NCT07215767?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2025-09-16. Estimated completion is 2026-08.
What conditions does trial NCT07215767 study?
This clinical trial studies the following conditions: Dentin Hypersensitivity.
What interventions are being tested in trial NCT07215767?
The interventions under investigation include: Stannous fluoride and Potassium nitrate Dentifrice (DRUG), Stannous fluoride Dentifrice (DRUG), Potassium nitrate Dentifrice (DRUG), Vehicle Dentifrice (DRUG).
Who is sponsoring clinical trial NCT07215767?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215767 being conducted?
This trial has 3 study locations across Florida, Indiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dentin Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers
RECRUITING
-
A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes
RECRUITING · NA
-
A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity
COMPLETED · NA
-
A Comparison Study of Hypersensitivity Treatment
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI